The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases

Molecular Medicine

Volumn 20, Issue 1, 2014, Pages 138-146

  Magna, Melinda ^a   Pisetsky, David S ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALARMIN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; DOUBLE STRANDED DNA; DOUBLE STRANDED RNA; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACETYLATION; ANKYLOSING SPONDYLITIS; APOPTOSIS; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOPHAGY; BEHCET DISEASE; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CHEMOTAXIS; CRYSTAL; CRYSTAL INDUCED ARTHRITIS; CYTOKINE PRODUCTION; CYTOLOGY; DENDRITIC CELL; EXTRACELLULAR SPACE; GENE TRANSLOCATION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MACROPHAGE; MOLECULAR DYNAMICS; MONOCYTE; MYOSITIS; NETOSIS; NONHUMAN; OXIDATION REDUCTION STATE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PYROPTOSIS; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYNOVIAL FLUID LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE LEVEL;

ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; CHEMOKINE CXCL12; CHEMOTAXIS; CYSTEINE; CYTOKINES; GENE EXPRESSION REGULATION; HMGB1 PROTEIN; HUMANS; INFLAMMATION; NUCLEOSOMES; OXIDATION-REDUCTION; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CXCR4; TOLL-LIKE RECEPTOR 4;

EID: 84898738420     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2013.00164     Document Type: Article

References (70)

1. Andersson U, Tracey KJ. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29:139-62.
2. Harris HE, Andersson U, Pisetsky DS. (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8:195-202.
3. Yang H, Antoine DJ, Andersson U, Tracey KJ. (2013) The many faces of HMGB1: a molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J. Leukoc. Biol. 93:856-73.
4. Andersson U, Harris HE. (2010) The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim. Biophys. Acta. 1799:141-8.
5. Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-51.
6. Pullerits R, et al. (2003) High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48:1693-700.
7. Taniguchi N, et al. (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48:971-81.
8. Kokkola R, et al. (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 48:2052-8.
9. Ulfgren AK, et al. (2004) Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 50:1586-94.
10. Popovic K, et al. (2005) Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 52:3639-45.
11. Ek M, Popovic K, Harris HE, Nauclér CS, Wahren-Herlenius M. (2006) Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren ′s syndrome. Arthritis Rheum. 54:2289-94.
12. Grundtman C, et al. (2010) Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J. 24:570-8.
13. Ahn JK, Cha HS, Bae EK, Lee J, Koh EM. (2011) Extracellular high-mobility group box 1 is increased in patients with Behcet's disease with intestinal involvement. J. Korean Med. Sci. 26:697-700.
14. Mitroulis I, et al. (2011) Neutrophil extracellular trap formation is associated with IL-1ttand autophagy-related signaling in gout. PLoS One. 6:e29318.
15. Abdulahad DA, et al. (2012) Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res. Ther. 14:R184.
16. Maugeri N, et al. (2012) Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity. 45:584-7.
17. Abdulahad DA, et al. (2013) High mobility group box 1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE). Lupus. 22:597-606.
18. Oktayoglu P, et al. (2013) Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life. Rheumatol. Int. 33:1327-31.
19. Schierbeck H, et al. (2013) HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J. Rheumatol. 40:1604-13.
20. Cato L, Stott K, Watson M, Thomas JO. (2008) The interaction of HMGB1 and linker histones occurs through their acidic and basic tails. J. Mol. Biol. 384:1262-72.
21. Štros M. (2010) HMGB proteins: interactions with DNA and chromatin. Biochim. Biophys. Acta. 1799:101-13.
22. Thomas JO, Stott K. (2012) H1 and HMGB1: modulators of chromatin structure. Biochem. Soc. Trans. 40:341-346.
23. Gardella S, et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a nonclassical, vesicle-mediated secretory pathway. EMBO Rep. 3:995-1001.
24. Bonaldi T, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:5551-60.
25. Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191-5.
26. Rovere-Querini P, et al. (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5:825-30.
27. Galluzzi L, et al. (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 19:107-20.
28. Hori O, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270:25752-61.
29. Park JS, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370-77.
30. Park JS, et al. (2006) High mobility group box 1 protein interacts with multiple toll-like receptors. Am. J. Physiol. Cell Physiol. 290:C917-24.
31. Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P. (2005) Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35:2184-90.
32. Ivanov S, et al. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpGDNA. Blood. 110:1970-81.
33. Dintilhac A, Bernués J. (2002) HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J. Biol. Chem. 277:7021-8.
34. Bianchi ME. (2009) HMGB1 loves company. J. Leukoc. Biol. 86:573-6.
35. Wähämaa H, et al. (2011) High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res. Ther. 13:R136.
36. Hreggvidsdóttir HS, et al. (2012) High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol. Med. 18:224-30.
37. Leclerc P, et al. (2013) IL-1(/HMGB1 complexes promote the PGE2 biosynthesis pathway in synovial fibroblasts. Scand. J. Immunol. 77:350-60.
38. Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519-28.
39. Yang H, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18:250-9.
40. Venereau E, Schiraldi M, Uguccioni M, Bianchi ME. (2013) HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol. Immunol. 55:76-82.
41. Valdés-Ferrer SI, et al. (2013) HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6C (high) inflammatory monocytes in murine sepsis survivors. J. Intern. Med. 274:381-90.
42. Beyer C, et al. (2012) The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. Innate Immun. 18:727-37.
43. Nagata S, Hanayama R, Kawane K. (2010) Autoimmunity and the clearance of dead cells. Cell. 140:619-30.
44. Kruse K, et al. (2010) Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis. 15:1098-113.
45. Pisetsky DS. (2014) The translocation of nuclear molecules during inflammation and cell death. Antioxid. Redox Signal. 20:1117-25
46. Bell CW, Jiang W, Reich CF 3rd, Pisetsky DS. (2006) The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 291:C1318-25.
47. Kazama H, et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspasedependent oxidation of high-mobility group box-1 protein. Immunity. 29:21-32.
48. Thorburn J, et al. (2009) Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 16:175-83.
49. Tang D, et al. (2010) HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 29:5299-310.
50. Urbonaviciute V, et al. (2009) Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity. 42:305-7.
51. Miao EA, Rajan JV, Aderem A. (2011) Caspase-1-induced pyroptotic cell death. Immunol. Rev. 243:206-14.
52. Nyström S, et al. (2013) TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO J. 32:86-99.
53. Lamkanfi M, et al. (2010) Inflammasomedependent release of the alarmin HMGB1 in endotoxemia. J. Immunol. 185:4385-92.
54. Brinkmann V, Zychlinsky A. (2012) Neutrophil extracellular traps: is immunity the second function of chromatin? J. Cell Biol. 198:773-83.
55. Kessenbrock K, et al. (2009) Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15:623-5.
56. Garcia-Romo GS, et al. (2011) Netting neutrophils are major inducers of Type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3:73ra20.
57. Yipp BG, et al. (2012) Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat. Med. 18:1386-93.
58. Xu J, et al. (2009) Extracellular histones are major mediators of death in sepsis. Nat. Med. 15:1318-21.
59. Pisetsky DS. (2012) The origin and properties of extracellular DNA: from PAMP to DAMP. Clin. Immunol. 144:32-40.
60. Tian J, et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 8:487-96.
61. Urbonaviciute V, et al. (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205:3007-18.
62. Wen Z, et al. (2013) Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J. Immunol. 190:5411-22.
63. Sun W, et al. (2013) Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Lab. Invest. 93:626-38.
64. Wang Q, et al. (2013) Pyroptotic cells externalize eat-me and release find-me signals and are efficiently engulfed by macrophages. Int. Immunol. 25:363-72.
65. Antoine DJ, et al. (2012) Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Heptaol. 56:1070-9.
66. Harrill AH, et al. (2012) The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin. Pharmacol. Ther. 92:214-20.
67. Musumeci D, Roviello GN, Montesarchio D. (2013) An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol. Ther. 141:347-57.
68. Zhou Y, et al. (2013) Protective effects of necrostatin-1 against concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm. 2013:706156.
69. Peter ME. (2008) ROS eliminate danger. Immunity. 29:1-2.
70. Nathan C, Ding A. (2010) Nonresolving inflammation. Cell. 140:871-82.